共 88 条
[1]
Jänne PA(2005)Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology J Clin Oncol 23 3227-3234
[2]
Engelman JA(2005)Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2445-2459
[3]
Johnson BE(2005)Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527-1537
[4]
Baselga J(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[5]
Arteaga CL(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121-128
[6]
Thatcher N(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388
[7]
Chang A(2005)Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123-132
[8]
Parikh P(2006)Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 24 3831-3837
[9]
Mok TS(2011)Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer Lung Cancer 74 98-102
[10]
Wu YL(2002)Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, inpatients with five selected solid tumor types J Clin Oncol 20 4292-4302